NEWS

The board of directors of AMS BioteQ (TPE:6864) approved the appointment of Deputy General Manager Zhang Yiwei.

AMS BioteQ (TPE:6864) will conduct a rights issue of 40 million NT dollars, with the ex-rights date on September 12. The issue price is set at 28 NT dollars per share.

We would like to thank Yoshiaki Tsukamoto, Director of the Japan Bioindustry Association, Tetsu Yamada, Department Head, Yu-Hong Chen, Consultant of the Bioindustry Development Association, and Project Manager Chih-Ling Hsia and Specialist Hsin-Yuan Wang from the Metalworking Center for personally visiting Yuan Zhang.

AMS BioteQ (stock code: 6864-TW) officially signed a distributor contract for the mainland China region with VITAHOUSE PHARAC PTY CO., LIMITED on the 17th of this month. This is an important step for us to capture the China's big health market.

We sincerely appreciate everyone’s long-term support and care for AMS BioteQ. On April 30, 2022, our company officially moved into the Kaohsiung Shi-Wei Financial Center. With a design layout brimming with modernity, we showcase our innovation and expertise, enhancing our overall service capability.

Yuanta Securities has been appointed as the recommended securities firm for AMS BioteQ Emerging Stock Board since February 25, 2022!